4/A: Zura Bio Officer Corrects Transaction Code in Form 4 Amendment
SEC Filing
Kiran Nistala, an officer of Zura Bio Ltd, files an amendment to a previously submitted Form 4 to correct the transaction code for a purchase of Class A ordinary shares.
Summary
- Kiran Nistala, an officer of Zura Bio Ltd, filed an amendment to a Form 4 on September 9, 2024, to correct an administrative error in the original filing from April 24, 2024.
- The amendment changes the transaction code from 'P' (incorrect) to 'A' (correct) for the acquisition of 3,195 Class A ordinary shares on April 22, 2024.
- These shares were acquired through a private placement transaction under a Securities Purchase Agreement dated April 18, 2024, at a price of $3.13 per share.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing correcting an error. It doesn't indicate any significant positive or negative developments for the company, but accuracy in reporting is always viewed favorably.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's securities, ensuring transparency and compliance with SEC regulations.
Stakeholder Impact
- The correction of the transaction code ensures accurate reporting to shareholders and the public.
Key Dates
| Date | Description |
|---|---|
| 04/18/2024 | Date of the Securities Purchase Agreement between Zura Bio and the Reporting Person. |
| 04/22/2024 | Date of the transaction where 3,195 Class A ordinary shares were acquired. |
| 04/24/2024 | Date of the original Form 4 filing with the incorrect transaction code. |
| 09/09/2024 | Date of the amended Form 4 filing to correct the transaction code. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.